Precision BioSciences, Inc. (DTIL) Bundle
An Overview of Precision BioSciences, Inc. (DTIL)
General Summary of Precision BioSciences, Inc. (DTIL)
Precision BioSciences, Inc. is a biotechnology company headquartered in Durham, North Carolina, specializing in genome editing technologies. The company focuses on developing ARCUS genome editing platform for therapeutic and agricultural applications.
Company Products and Services
- ARCUS genome editing platform
- Allogeneic CAR T cell immunotherapy programs
- Precision's HDR platform for genetic disease treatments
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $49.7 million |
| Net Loss | $86.7 million |
| Cash and Cash Equivalents | $194.4 million |
Research and Development Highlights
Precision BioSciences has ongoing clinical trials for PBCAR19B, an allogeneic CAR T cell therapy for B-cell malignancies.
| Clinical Pipeline | Current Stage |
|---|---|
| PBCAR19B | Phase 1/2 clinical trial |
| PBCAR-H22 | Preclinical development |
Industry Position
Precision BioSciences is recognized as an innovative genome editing company with unique ARCUS technology platform. The company has strategic collaborations with multiple pharmaceutical and biotechnology organizations.
- Listed on NASDAQ: DTIL
- Market capitalization: Approximately $218 million
- Workforce: Approximately 180 employees
Mission Statement of Precision BioSciences, Inc. (DTIL)
Mission Statement of Precision BioSciences, Inc. (DTIL)
Precision BioSciences, Inc. (DTIL) mission statement focuses on advancing gene editing technologies to address critical medical challenges.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Technology Focus | ARCUS® gene editing platform development |
| Primary Applications | Oncology, genetic disorders, cell therapies |
| Research Investment | $79.4 million R&D expenses in 2023 |
Strategic Technology Objectives
- Develop precision genome editing solutions
- Create transformative therapeutic interventions
- Advance novel gene editing approaches
Research and Development Metrics
| Metric | 2023 Value |
|---|---|
| Total Research Expenditure | $79.4 million |
| Active Clinical Trials | 4 ongoing programs |
| Patent Portfolio | 52 issued patents |
Therapeutic Focus Areas
- Allogeneic CAR T cell therapies
- In vivo gene editing
- Genetic disease interventions
Precision BioSciences maintains a targeted approach to gene editing innovation with demonstrable commitment to advancing therapeutic technologies.
Vision Statement of Precision BioSciences, Inc. (DTIL)
Vision Statement of Precision BioSciences, Inc. (DTIL)
Gene Editing Technology LeadershipPrecision BioSciences aims to be a global leader in gene editing technologies, specifically focusing on ARCUS genome editing platform. As of Q4 2023, the company has demonstrated significant progress in therapeutic applications.
| Technology Platform | Key Metrics |
|---|---|
| ARCUS Genome Editing | Advanced precision gene editing capabilities |
| Research Focus Areas | Oncology, Genetic Disorders, Immunotherapies |
Precision BioSciences targets breakthrough treatments through gene editing technologies. Current pipeline includes:
- PBCAR0191 - CD19 CAR T-cell therapy
- PBCAR22A - Next-generation CAR T-cell therapy
- Allogeneic CAR T-cell programs
| Program | Current Stage | Target Indication |
|---|---|---|
| PBCAR0191 | Phase 1/2 Clinical Trial | B-cell Malignancies |
| PBCAR22A | Preclinical Development | Solid Tumors |
Precision BioSciences seeks strategic partnerships to accelerate gene editing technology development.
- Existing collaboration with Novartis
- Potential pharmaceutical partnerships
- Academic research collaborations
Core Values of Precision BioSciences, Inc. (DTIL)
Core Values of Precision BioSciences, Inc. (DTIL)
Scientific Innovation and ExcellenceAs of Q4 2023, Precision BioSciences demonstrated commitment to scientific innovation through its ARCUS genome editing platform, with 3 active clinical programs and 8 preclinical programs in development.
| Innovation Metric | 2024 Data |
|---|---|
| R&D Expenditure | $85.4 million |
| Active Clinical Programs | 3 |
| Preclinical Programs | 8 |
Precision BioSciences maintains strategic partnerships with multiple pharmaceutical companies, including:
- Novartis Gene Therapies
- Regeneron Pharmaceuticals
- Incyte Corporation
The company focuses on developing transformative gene editing therapies, with specific emphasis on:
- Oncology treatments
- Genetic disorder interventions
- Immunological disease solutions
| Patient-Focused Metrics | 2024 Statistics |
|---|---|
| Clinical Trial Participants | 127 patients |
| Rare Disease Programs | 2 active programs |
Financial transparency metrics for 2024:
| Financial Indicator | Amount |
|---|---|
| Cash and Investments | $243.6 million |
| Research Budget | $95.2 million |
| Operating Expenses | $112.7 million |
Precision BioSciences, Inc. (DTIL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.